Notably, in every approach we have gained valuable insights into our cohort of 71 CRC patients, e.g. 1/APC-TCF7L2 synthetic lethality pair that could be used in some carriers of variants in APC from our cohort, 2/VPS4A-VPA4B - a known synthetic lethality pair that was identified as a potentially personalized approach to one of our patients, importantly this gene pair could be an interesting target not only for CRC patients but also for carriers of the same CNV in other tumors and 3/a plethora of neoepitopes for every case that could be useful in personalized immunotherapies. This evidence concerns the gene VPS4A and colorectal carcinoma.